Join Growin Stock Community!

Tekla life sciences investorsHQL.US Overview

US StockFinancial Services
(No presentation for HQL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HQL AI Insights

HQL Overall Performance

HQL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HQL Recent Performance

-1.89%

Tekla life sciences investors

1.79%

Avg of Sector

-0.31%

S&P500

HQL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HQL Key Information

HQL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HQL Profile

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Price of HQL

HQL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HQL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.43
PE Ratio (TTM)
5.97
Forward PE
-
PS Ratio (TTM)
254.24
PB Ratio
0.96
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
1830.03%
Revenue Growth (YoY)
-87.89%
Profit Growth (YoY)
-86.81%
3-Year Revenue Growth
-42.69%
3-Year Profit Growth
-35.89%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.43
PE Ratio (TTM)
5.97
Forward PE
-
PS Ratio (TTM)
254.24
PB Ratio
0.96
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
1830.03%
Revenue Growth (YoY)
-87.89%
Profit Growth (YoY)
-86.81%
3-Year Revenue Growth
-42.69%
3-Year Profit Growth
-35.89%

  • When is HQL's latest earnings report released?

    The most recent financial report for Tekla life sciences investors (HQL) covers the period of 2024Q4 and was published on 2024/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HQL's short-term business performance and financial health. For the latest updates on HQL's earnings releases, visit this page regularly.

  • What is the operating profit of HQL?

    According to the latest financial report, Tekla life sciences investors (HQL) reported an Operating Profit of -1.27M with an Operating Margin of -66.17% this period, representing a growth of 88.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is HQL's revenue growth?

    In the latest financial report, Tekla life sciences investors (HQL) announced revenue of 1.91M, with a Year-Over-Year growth rate of -93.52%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • Does HQL go with three margins increasing?

    In the latest report, Tekla life sciences investors (HQL) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -66.17%%, and net margin of 1,830.03%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HQL's profit trajectory and future growth potential.

  • Is HQL's EPS continuing to grow?

    According to the past four quarterly reports, Tekla life sciences investors (HQL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of HQL?

    The latest valuation data shows Tekla life sciences investors (HQL) has a Price-To-Earnings (PE) ratio of 3.1 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.